<DOC>
	<DOCNO>NCT02506881</DOCNO>
	<brief_summary>This randomize double-blind crossover study pharmacokinetics , pharmacodynamics safety BCD-066 ( darbepoetin alfa manufacture CJSC BIOCAD , Russia ) Aranesp® ( Amgen Europe B.V. , Netherlands ) healthy volunteer . The purpose study demonstrate equivalence pharmacokinetics , pharmacodynamics safety parameter single subcutaneous intravenous injection . Each drug administer volunteer dose 1 µg per kilogram single subcutaneous intravenous injection interval least 25 day .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study BCD-066 Compared Aranesp® Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Signed write informed consent Male gender Age 18 45 year inclusively Body mass index ( BMI ) 19 29 kg/m2 inclusively Hemoglobin level 120160 g/l ( 12 16 g/dL ) inclusively 14 day prior first study drug administration White blood cell count ≥3,0×109/L , Platelet count ≥140×109/L 14 day prior first study drug administration Subjects must good health determine medical history , medical examination , electrocardiogram , serum biochemistry , haematology , serology urinalysis Absence history systematic alcohol drug abuse Ability volunteer , investigator 's opinion , follow study protocol procedures requirement Willingness volunteer sexual partner childbearing potential use reliable contraception method start 2 week inclusion study 4 week receive last dose investigational product . This criterion applicable patient underwent surgical sterilization . Reliable contraceptive measure include one barrier method combination one follow method : spermicide , intrauterine device oral contraceptive use participant 's partner Consent avoid alcohol intake within 24 hour 48 hour administration test reference drug Clinically significant abnormality ECG laboratory test , could interfere objective study safety volunteer . Clinically significant illness within 4 week prior screen visit Subjects past present history liver disease , angina , renal disease , hypertension , epilepsy , cardiovascular , cerebrovascular , peripheral vascular disease thrombocytosis History oncological disease Prior exposure erythropoietin , darbepoetin Prior exposure IV iron supplementation ( within 2 year randomisation ) Subjects used medication , include overthecounter drug , herbal medication , nutritional supplement within 14 day prior IDs administration exception paracetamol ( acetaminophen ) 3g per day ibuprofen 1g per day Subjects smoke 10 cigarette per day Subjects donate 450 ml blood within 1 month prior ID injection Epileptic seizure within 6 month prior ID injection Major surgery within 1 month prior enrollment study Inability install intravenous catheter ( e.g. , due skin disease ) Subjects received experimental drug within 3 month precede 1st ID administration Subjects clinically significant history drug hypersensitivity allergic disease Possibility subject cooperate requirement protocol set volunteer information Subjects consume excessive amount caffeine ( 5 cup coffee per day ) Participation clinical study precede participation study within 3 month prior 1st ID administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>